-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,070.276 in Common Shares

PUBT·11/10/2026 15:08:20
Listen to the news
AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,070.276 in Common Shares
  • AIM ImmunoTech CEO and President Thomas K. Equels purchased 31,298 common shares at $0.162 per share.
  • The purchase increased his directly held common stock to 254,095 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050892), on November 10, 2026, and is solely responsible for the information contained therein.